Clinical management, consisting of regular monitoring, and for a minority of people pharmaceutical treatment, reduces hepatitis B disease progression.

Of all people with hepatitis B in Australia, only 13 per cent are clinically managed and of the 5 per cent that do receive pharmaceutical treatment, 20 per cent do not regularly take their medication.

A major gap in the public health response to hepatitis B is to identify the reasons for the reported ‘non-compliance’ of people with hepatitis B to the current model of care or identifying the elements of an effective clinical guideline and future model of care.

Timeline

2020 – 2021